Main results
This systematic review includes three trials with a combined total of 164 participants who had moderate to severe paraquat poisoning.
Patients who received glucocorticoid with cyclophosphamide in addition to standard care had a lower risk of death at final follow-up than those receiving standard care only (RR 0.72; 95% CI 0.59 to 0.89).
Authors' conclusions
Based on the findings of three small RCTs of moderate to severely poisoned patients, glucocorticoid with cyclophosphamide in addition to standard care may be a beneficial treatment for patients with paraquat-induced lung fibrosis. To enable further study of the effects of glucocorticoid with cyclophosphamide for patients with moderate to severe paraquat poisoning, hospitals may provide this treatment as part of an RCT with allocation concealment.
P L A I N L A N G U A G E S U M M A R Y

Using steroids and cyclophosphamide together as a treatment for paraquat poisoning
Paraquat is an effective and widely used herbicide but is also a lethal poison. In many developing countries paraquat is widely available and inexpensive, making poisoning prevention difficult. However most of the people who become poisoned from paraquat have taken it as a means of suicide.
Standard care for removing paraquat from the body involves vomiting, consuming activated charcoal or Fuller's Earth (which absorbs paraquat), and blood filtering. This review aims to assess the effects of giving patients steroids and cyclophosphamide in addition to standard care to prevent death after paraquat poisoning.
We found three small randomised controlled trials in which patients with moderate or severe poisoning were given either standard care only or standard care and steroids and cyclophosphamide. When the results of the three studies were combined, we found that patients who were given standard care and steroids and cyclophosphamide had a reduced risk of death of about 28% (statistically estimated likely range of reduced deaths from 41% to 11%) compared with patients given standard care alone. However, the studies were small and one was of low methodological quality so the benefit of this treatment should be interpreted with caution. To understand the effects of this treatment for poisoned patients better, we recommend it be given in the context of a randomised controlled trial so that future results can be analysed with similar studies.
B A C K G R O U N D
Paraquat is one of the most widely used herbicides worldwide. It is commercially produced and has been sold in around 130 countries since 1961, despite its fatal toxicity to humans (Tomlin 1994). Because it is inexpensive and widely available, it is difficult to prevent paraquat poisoning. Paraquat poisoning by accidental or voluntary ingestion accounts for numerous deaths each year, predominantly in developing countries where its use is less stringently controlled than in Europe or the US.
An epidemiological study of poisoning in rural Sri Lanka found an incidence of poisoning of 75 per 100,000 population, with a death rate of 22 per 100,000 population. The incidence and death rates from poisoning were highest in the 15 to 34 years age group, and there were significant differences in the incidence of poisoning among different ethnic groups. In this study, paraquat was the most common poisoning agent (Hettiarachchi 1989).
In China, paraquat poisoned patients are usually women and children in impoverished rural areas, who have received a low standard of education and are often unfairly treated. In many cases, the decision to drink paraquat is impulsive and follows an intense interpersonal conflict (Wang 2008).
Description of the condition
The prognosis in paraquat poisoning is associated with the amount of toxin ingested.
• In low-dose poisoning (< 20 mg of paraquat ion per kg of body weight) patients are often asymptomatic, or may develop vomiting or diarrhoea, but have a good chance of recovery.
• In moderate-dose poisoning (20 mg to 40 mg of paraquat ion per kg of body weight), initial renal and hepatic dysfunction is common. Mucosal damage may become apparent with sloughing of the mucous membranes in the mouth. Difficulty in breathing may develop after a few days in more severe cases. After about 10 days, although renal function often returns to normal, radiological signs of lung damage usually develop. Lung damage is usually followed by irreversible massive pulmonary fibrosis manifested by the progressive loss of the lungs' ability to breathe, and deterioration continues until the patient eventually dies, between two and four weeks after ingestion.
• In high-dose poisoning (> 40 mg paraquat ion per kg of body weight), toxicity is much more severe and death occurs early (within 24-48 h) from multiple organ failure. Vomiting and diarrhoea are severe, with considerable fluid loss. Renal failure, cardiac arrhythmias, coma, convulsions and oesophageal perforation leads to death (WHO 2009).
Description of the intervention
The care of a paraquat poisoned person involves reducing the quantity of paraquat ingested and removing paraquat from the bloodstream. Vomiting should be induced as soon as possible to prevent further absorption of the toxin (Dinham 1996) . Upon arrival at the emergency department, further interventions may include gastric aspiration, gastric lavage, repeated administration of the absorbents activated charcoal or Fuller's Earth, and purgatives such as mannitol or sorbitol (WHO 2009). Haemodialysis, haemofiltration, and haemoperfusion can be instituted with the aim of reducing the load of poison in the blood, but these interventions have no confirmed effects for improving survival (Suzuki 1993; Koo 2002), mainly because paraquat accumulates in the lungs. Paraquat molecules selectively accumulate in the lungs, leading to irreversible pulmonary fibrosis, which is also known as 'paraquat lung' (Smith 1975; Fukuda 1985) . This accumulation process begins immediately after ingestion and lasts from two to four weeks. A large proportion of patients appear asymptomatic until signs of breathing difficulty emerge; it is difficult to predict the outcome of a patient who appears normal but is actually suffering lung fibrosis (Eddleston 2003). While numerous methods are available to reduce paraquat concentration in the bloodstream, the progression of lung injury through the deposited paraquat is a major concern. Using glucocorticoid and cyclophosphamide in combination as a means of suppressing the immunoreactions that cause lung damage has been tested since the 1970s (Eddleston 2003), but the effectiveness of this treatment is unknown. The timing of providing treatment, the duration of treatment and the dosage of drugs can vary depending on the needs of the patient.
How the intervention might work
After being actively accumulated by lung cells, paraquat catalyses the formation of certain chemicals, namely superoxide, singlet oxygen, hydroxyl and peroxide radicals. These chemicals are also used by the immune system as 'weapons' to destroy items recognised as foreign to the human body (Smith 1988). It is believed that immunosuppressive methods prevent the immune system from producing such chemicals thereby reducing damage. At the same time, the immunosuppressive agents are intended to halt the progress of fibrosis, which is a part of immune reaction (Jaeschke 1997).
Why it is important to do this review
Though it has been inferred from experimental (Lee 1984) and clinical experience (Agarwal 2006) that immunosuppressive therapy might reduce deaths among paraquat poisoned patients, there has been no conclusion on the effectiveness of this treatment. Considering the hazards associated with immunosuppressive drugs (Winsett 2004), for example by making patients more prone to infection in the long term, it is timely to have a systematic review on this topic to support decision-making or suggest further research.
O B J E C T I V E S
To assess the effects of glucocorticoid with cyclophosphamide on mortality in patients with paraquat-induced lung fibrosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) were included.
Types of participants
Any person with paraquat poisoning.
Types of interventions
All patients were to receive standard care plus either the intervention or control.
• Intervention: glucocorticoid with cyclophosphamide in combination.
• Control: placebo, standard care alone or any other therapy in addition to standard care.
Studies that focused on any single immunosuppressant or other combinations of therapies were excluded.
Types of outcome measures
• Mortality at 30 days following the ingestion of paraquat.
• All-cause mortality at the end of the follow-up period.
Search methods for identification of studies
In order to reduce publication and retrieval bias we did not restrict our search by language, date or publication status. Search strategies with notes for this update are listed in Appendix 1. Search methods and strategies for previous versions of the review can be found in Appendix 2.
Electronic searches
The Cochrane Injuries Group's Trials Search Co-ordinator searched the following: 
Searching other resources
We searched the Internet through search engines Google.com and Baidu.com, using the term 'clinical trial & paraquat'. We also checked the reference lists of reports and literature reviews on paraquat poisoning for potentially relevant published or unpublished trials. We contacted the authors of the included trials for further information.
Data collection and analysis
Selection of studies
The search results from English language databases were screened independently by LL, BC, DB and ES. The results from the Chinese databases were screened independently by LL and YC. The full-text versions of potentially relevant trials were obtained and assessed. Duplicate reports were identified and noted. LL and BC disagreed about the inclusion of the Afzali 2008 study due to the use of alternation as the method of randomisation. YC moderated the discussion on inclusion of this trial, and it was agreed that the trial would be included but noted as being of high risk of bias.
Data extraction and management
Data from the three included trials were extracted independently by LL, BC and ES. Data were extracted on the study design, number of participants in the intervention and control groups, the number of deaths in each group on an intention-to-treat basis, and loss to follow-up in each trial. Information on the methodology of each trial was recorded for assessment of the risk of bias, as described below. Data were analysed using Review Manager software (RevMan 2011).
Assessment of risk of bias in included studies
Three review authors (LL, BC and ES) independently evaluated the risk of bias for each included trial in the following domains: sequence generation, allocation concealment, blinding, incomplete reporting, selective outcome reporting and any other sources of bias. To facilitate a valid judgement, we wrote to the contact person of each trial to request further information. Our judgement was made according to the criteria defined in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), with an assessment of 'low risk of bias' or 'high risk of bias' made for each criteria. 'Unclear risk of bias' indicates that not enough information was provided for us to make a judgement on a particular area of bias. The judgements can be found in the 'Risk of bias' tables below, and a summary of the judgements are given in Figure 1 and Figure 2 . 
Measures of treatment effect
The risk ratio (RR) and 95% confidence interval (CI) was calculated for each trial on an intention-to-treat basis. Data for all-cause mortality at final follow-up were summarised in a meta-analysis using a fixed-effect model.
Dealing with missing data
The amount of loss to follow-up in each trial was assessed.
Assessment of heterogeneity
Clinical heterogeneity was assessed by considering the design of each trial. Where suspicion of clinical heterogeneity arose, the differences in study design among trials was considered. Where possible and appropriate, the statistical heterogeneity was examined using the Chi 2 test. A P value below 0.10 indicated heterogeneity but was interpreted with caution. The I 2 statistic was calculated to assess the attribution of heterogeneity to the diversity of results from different trials.
Assessment of reporting biases
Due to the small number of trials included in the review, we did not investigate reporting bias through a funnel plot.
The English language electronic search has retrieved a total of 2723 records across all years. Four RCTs (three completed and one ongoing) were identified in the first version of this review, and no new eligible studies have subsequently been found. LL identified a total of 934 reports through a Chinese language search on Chinese language databases; none of them met the inclusion criteria. LL identified one report while searching Google.com using the term 'clinical trial & paraquat', which was later excluded (Tsai 2009). No additional eligible RCTs were identified through screening reference lists or literature reviews.
Included studies
Three trials with a combined total of 164 participants are in- 
Excluded studies
Two trials were excluded: in one trial the intervention was methylprednisolone only (Tsai 2009), and the other was a historical controlled trial (Perriens 1992).
Risk of bias in included studies
The trial by Lin 2006 had a relatively low risk of bias. The trial by Lin 1999 randomised all urine-positive patients but presented the outcomes for those who died within one week of poisoning separately from those who survived longer. Presenting the data separately is reasonable to a certain extent given the specific clinical features of paraquat poisoning, but also suggests reporting bias. The exact methods used for patient selection, randomisation and sequence concealment were not reported in the Afzali 2008 study but we were able to gain the necessary details through contact with the author and determined that the trial was at high risk of bias. Our judgements of the risk of bias are recorded in the 'Risk of bias' tables, and are displayed in Figure 1 and Figure 2 .
Allocation
The Lin 2006 study used an appropriate method of sequence generation and allocation concealment. Lin 1999 generated the randomisation sequence using a random number table, but did not conceal the sequence. Afzali 2008 used alternation with no concealment, according to the author.
Blinding
None of the trials mentioned blinding of the treating physicians or patients. In Lin 1999 and Lin 2006 the statistician who contributed to the trial report was blinded to the allocation.
Incomplete outcome data
Mortality was the outcome of interest, and was reported in full in all trials.
Selective reporting
There was no selective reporting of mortality. The Lin 1999 study presented the mortality data by severity of poisoning and randomisation group, which appears to have been a post-hoc decision in the style of presenting results. However, we analysed the data according to intention to treat, which maintained the original randomisation.
Other potential sources of bias
No other potential source of bias was found.
Effects of interventions
All-cause mortality at the end of the follow-up period
All three trials reported death at the end of the follow-up period (Analysis 1.1). Patients who received glucocorticoid with cyclophosphamide in addition to standard care had a lower risk of death than those receiving standard care alone (RR 0.72; 95% CI 0.59 to 0.89). There was some statistical heterogeneity between trials (Chi 2 = 5.96, degrees of freedom (df ) = 2 (P = 0.05); I 2 = 66%).
D I S C U S S I O N
Summary of main results
This systematic review includes three trials (one of low methodological quality) with a combined total of 164 participants who had moderate to severe paraquat poisoning. Participants who received glucocorticoid with cyclophosphamide in addition to standard care had a lower risk of death than those receiving standard care alone.
Overall completeness and applicability of evidence
There are few RCTs involving paraquat poisoned patients. The review includes three small RCTs, one of which is of low quality.
To enable further study of the effects of glucocorticoid and cyclophosphamide for paraquat poisoned patients, hospitals should provide this treatment as part of an RCT with allocation concealment. The findings of this review should be interpreted with caution until more data become available. A large RCT in Sri Lanka has been terminated early due to the government's ban on the sale of paraquat. The results of this study will be included into the review in due course (if possible before the end of 2014). The study is described in the Characteristics of ongoing studies table.
Potential biases in the review process
This review was conducted according to predefined inclusion criteria and methodology to select and appraise eligible studies. The search for trials was extensive, and was conducted on English and Chinese language databases. Publication bias is a consideration in any systematic review. Although there were only three small trials included in this review, we believe that due to the extent of the search for trials, these were the only RCTs addressing this research question at the time of the search.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Based on the findings of three small RCTs of moderate to severely poisoned patients, glucocorticoid with cyclophosphamide in addition to standard care may be beneficial for patients with paraquatinduced lung fibrosis. The finding of this review should be interpreted with caution until more data become available.
Implications for research
To enable further study of the effects of glucocorticoid with cyclophosphamide for patients with moderate to severe paraquat poisoning, hospitals may provide this treatment as part of an RCT with allocation concealment.
A C K N O W L E D G E M E N T S
We thank Karen Blackhall for providing the search strategy and the search of English language databases for previous versions of this review. We thank Xi Lv for searching Chinese language databases in 2012. ticipants were randomised into the study regardless of the severity of poisoning. We, the authors of this Cochrane review, have combined the results from the 2 tables on page 358 of their paper into the results of this review on an intention-to-treat basis to maintain the study investigators' original randomisation
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Other bias Low risk
We did not identify any other areas of bias. The presentation of results in the study report implies that the intervention is effective in moderately poisoned patients; but we have used an intention-to-treat analysis to summarise the findings in this review, which corrects this potential bias
Lin 2006
Methods Randomised controlled trial
Participants
Patients who: 1) arrived at the emergency department within 24 hours of ingesting paraquat, 2) were age 15 years or older, 3) had predicted mortality of > 50% and ≤ 90% according to the Hart 1984 formula, and 4) had urine sodium dithionite tests showing the colour dark blue or navy blue The exclusion criteria were: "Patients were excluded from the study if they had dermal exposure to paraquat; received intravascular injection of paraquat; did not have paraquat levels in biological fluids; arrived at the emergency room >24 hours after ingestion of paraquat; ingested paraquat due to major systemic diseases including cancer and heart, lung, renal, and liver diseases; or did not give informed consent." p.369
Interventions
All patients received: "To prevent absorption of paraquat from the gastrointestinal tract, activated charcoal 1 g/kg added to 250 mL of magnesium citrate was given through a nasogastric tube after gastric lavage with normal saline. In addition, all patients received two doses of 8-hr active charcoal-containing haemoperfusion therapy in the emergency room." p.369 The control group received: "After haemoperfusion therapy, the control group received dexamethasone 5 mg in an intravenous injection every 6 hrs until their arterial blood gas showed PaO2 11.5 kPa (80mm Hg) or they died." p.369 The intervention group received: "At the same time, the study group received pulse therapy with 15 mg/kg cyclophosphamide in 5% glucose saline 200 mL and 1 g of methylprednisolone in the other 200 mL of 5% glucose saline intravenously infused for 2 hrs per day. Cyclophosphamide was infused for 2 days and methylprednisolone for 3 day simultaneously. Preceding dexamethasone, a 5-mg intravenous injection every 6 hrs was given until the arterial blood gas showed PaO2 11.5 kPa (80 mm Hg). Repeated pulse therapy with 1 g of methylprednisolone in the other 200 mL of 5% glucose saline intravenously infused for 2 hrs per day for 3 days was given again if PaO2 was 8.64 kPa (60 mm Hg). In addition, 15mg/kg/day cyclophosphamide was infused for 1 day again if patients' white cell counts were 3000/m 3 and the duration was 2 wks after initial cyclophosphamide pulse therapy to avoid a severe leukopenia episode." p.369 
Outcomes Mortality
D A T A A N D A N A L Y S E S
W H A T ' S N E W
Last assessed as up-to-date: 15 April 2014.
Date Event Description
25 May 2014 New search has been performed The search has been updated to 15 April 2014. No new studies were identified. The results and conclusions remain the same The one ongoing study (ISRCTN85372848) was terminated early but some data are available. The study methodology and data have not been fully reported, but will be included into the review in due course 25 May 2014 New citation required but conclusions have not changed Deirdre Beecher has been added as an author. 
H I S T O R Y
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
In the protocol for this review, we said we would search the Chinese language databases Chinese bio-medical literature & retrieval system (CBM), Chinese medical current contents (CMCC), and Chinese medical academic conference (CMAC). These databases have now been included in the China National Knowledge Infrastructure database. For the 2014 upate, we searched the databases China National Knowledge Infrastructure ( ), WAN FANG DATA ( ), and VIP ( ). 
I N D E X T E R M S Medical Subject Headings (MeSH)
